The EC approved Libtayo – a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells – based on data from the global open-label, multi-centre phase 3 EMPOWER ...
Sensei Biotherapeutics (SNSE) announced initial results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug, a ...
These ready-made antibodies are suitable for developing selective and sensitive assays for bioanalysis and drug monitoring of cemiplimab. Cemiplimab acts as a checkpoint inhibitor by binding to PD-1 ...
Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...
1monon MSN
CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback